403 related articles for article (PubMed ID: 25529338)
21. A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo.
DeFeo-Jones D; Brady SF; Feng DM; Wong BK; Bolyar T; Haskell K; Kiefer DM; Leander K; McAvoy E; Lumma P; Pawluczyk JM; Wai J; Motzel SL; Keenan K; Van Zwieten M; Lin JH; Garsky VM; Freidinger R; Oliff A; Jones RE
Mol Cancer Ther; 2002 May; 1(7):451-9. PubMed ID: 12479263
[TBL] [Abstract][Full Text] [Related]
22. Targeting Toxins toward Tumors.
Franzyk H; Christensen SB
Molecules; 2021 Feb; 26(5):. PubMed ID: 33673582
[TBL] [Abstract][Full Text] [Related]
23. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
24. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
Akinboye ES; Brennen WN; Rosen DM; Bakare O; Denmeade SR
Prostate; 2016 Jun; 76(8):703-14. PubMed ID: 26835873
[TBL] [Abstract][Full Text] [Related]
25. Overcoming bcl-2- and p53-mediated resistance in prostate cancer.
DiPaola RS; Aisner J
Semin Oncol; 1999 Feb; 26(1 Suppl 2):112-6. PubMed ID: 10190792
[TBL] [Abstract][Full Text] [Related]
26. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
Janssen S; Jakobsen CM; Rosen DM; Ricklis RM; Reineke U; Christensen SB; Lilja H; Denmeade SR
Mol Cancer Ther; 2004 Nov; 3(11):1439-50. PubMed ID: 15542783
[TBL] [Abstract][Full Text] [Related]
27. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer.
Mhaka A; Denmeade SR; Yao W; Isaacs JT; Khan SR
Bioorg Med Chem Lett; 2002 Sep; 12(17):2459-61. PubMed ID: 12161157
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
Janssen S; Rosen DM; Ricklis RM; Dionne CA; Lilja H; Christensen SB; Isaacs JT; Denmeade SR
Prostate; 2006 Mar; 66(4):358-68. PubMed ID: 16302271
[TBL] [Abstract][Full Text] [Related]
29. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo.
DeFeo-Jones D; Garsky VM; Wong BK; Feng DM; Bolyar T; Haskell K; Kiefer DM; Leander K; McAvoy E; Lumma P; Wai J; Senderak ET; Motzel SL; Keenan K; Van Zwieten M; Lin JH; Freidinger R; Huff J; Oliff A; Jones RE
Nat Med; 2000 Nov; 6(11):1248-52. PubMed ID: 11062536
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
[TBL] [Abstract][Full Text] [Related]
31. Strategies for enzyme/prodrug cancer therapy.
Xu G; McLeod HL
Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
[TBL] [Abstract][Full Text] [Related]
32. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.
Levy O; Brennen WN; Han E; Rosen DM; Musabeyezu J; Safaee H; Ranganath S; Ngai J; Heinelt M; Milton Y; Wang H; Bhagchandani SH; Joshi N; Bhowmick N; Denmeade SR; Isaacs JT; Karp JM
Biomaterials; 2016 Jun; 91():140-150. PubMed ID: 27019026
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of peptide conjugates of phosphoramide mustard as prodrugs activated by prostate-specific antigen.
Wu X; Hu L
Bioorg Med Chem; 2016 Jun; 24(12):2697-706. PubMed ID: 27156193
[TBL] [Abstract][Full Text] [Related]
34. Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
Tokay E; Güngör T; Hacıoğlu N; Önder FC; Gülhan ÜG; Tok TT; Çelik A; Ay M; Köçkar F
Eur J Med Chem; 2020 Feb; 187():111937. PubMed ID: 31841727
[TBL] [Abstract][Full Text] [Related]
35. Preparation of Enzyme-Activated Thapsigargin Prodrugs by Solid-Phase Synthesis.
Zimmermann T; Christensen SB; Franzyk H
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914143
[TBL] [Abstract][Full Text] [Related]
36. Encapsulation of doxorubicin prodrug in heat-triggered liposomes overcomes off-target activation for advanced prostate cancer therapy.
Pereira S; Ma G; Na L; Hudoklin S; Kreft ME; Kostevsek N; Al-Jamal WT
Acta Biomater; 2022 Mar; 140():530-546. PubMed ID: 34954416
[TBL] [Abstract][Full Text] [Related]
37. Enzyme-catalyzed activation of anticancer prodrugs.
Rooseboom M; Commandeur JN; Vermeulen NP
Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
[TBL] [Abstract][Full Text] [Related]
38. Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy.
Jung M
Mini Rev Med Chem; 2001 Nov; 1(4):399-407. PubMed ID: 12369965
[TBL] [Abstract][Full Text] [Related]
39. Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients.
Vajda A; Marignol L; Foley R; Lynch TH; Lawler M; Hollywood D
Cancer Treat Rev; 2011 Dec; 37(8):643-54. PubMed ID: 21481534
[TBL] [Abstract][Full Text] [Related]
40. Proteases as activators for cytotoxic prodrugs in antitumor therapy.
Weidle UH; Tiefenthaler G; Georges G
Cancer Genomics Proteomics; 2014; 11(2):67-79. PubMed ID: 24709544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
